Abstract:What's new? Heterogeneity in breast cancer contributes to variations in treatment effectiveness. Patient‐derived organoids (PDOs) have emerged as promising models to predict individualized drug responses, though their applicability to breast cancer remains largely unexplored. Here, the authors established a biobank of breast cancer PDOs to evaluate their feasibility in predicting patient drug response. Experiments demonstrate that the PDOs accurately inherit the histologic and genetic characteristics of the breast tumors from which they are derived. Moreover, drug susceptibility in PDOs corresponded to clinical responses in matched patients. The findings highlight the potential utility of PDOs in guiding personalized therapy for breast cancer patients. Breast cancer has become the most commonly diagnosed cancer. The intra‐ and interpatient heterogeneity induced a considerable variation in treatment efficacy. There is an urgent requirement for preclinical models to anticipate the effectiveness of individualized drug responses. Patient‐derived organoids (PDOs) can accurately recapitulate the architecture and biological characteristics of the origin tumor, making them a promising model that can overtake many limitations of cell lines and PDXs. However, it is still unclear whether PDOs‐based drug testing can benefit breast cancer patients, particularly those with tumor recurrence or treatment resistance. Fresh tumor samples were surgically resected for organoid culture. Primary tumor samples and PDOs were subsequently subjected to H&E staining, immunohistochemical (IHC) analysis, and whole‐exome sequencing (WES) to make comparisons. Drug sensitivity tests were performed to evaluate the feasibility of this model for predicting patient drug response in clinical practice. We established 75 patient‐derived breast cancer organoid models. The results of H&E staining, IHC, and WES revealed that PDOs inherited the histologic and genetic characteristics of their parental tumor tissues. The PDOs successfully predicted the patient's drug response, and most cases exhibited consistency between PDOs' drug susceptibility test results and the clinical response of the matched patient. We conclude that the breast cancer organoids platform can be a potential preclinical tool used for the selection of effective drugs and guided personalized therapies for patients with advanced breast cancer.

Patient-derived Organoids (pdos) and PDO-derived Xenografts (pdoxs): New Opportunities in Establishing Faithful Pre-Clinical Cancer Models

Patient-derived organoids in precision cancer medicine

Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy

Creation and Development of Patient-Derived Organoids for Therapeutic Screening in Solid Cancer

Cancer organoids: A platform in basic and translational research

Patient-derived Organoids in Translational Oncology and Drug Screening

Progress in building clinically relevant patient‐derived tumor xenograft models for cancer research

Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy

Patient‐derived Cancer Organoids for Drug Screening: Basic Technology and Clinical Application

Patient Derived Ex-Vivo Cancer Models in Drug Development, Personalized Medicine, and Radiotherapy

Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells

Human patient derived organoids: an emerging precision medicine model for gastrointestinal cancer research

Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges

Research progress of patient-derived xenograft model

Organoids: approaches and utility in cancer research

Xenograft and organoid model systems in cancer research

Organoids for Cancer Research: Advances and Challenges

Establishment of patient‐derived organoids for guiding personalized therapies in breast cancer patients

Challenges and Prospects of Patient-Derived Xenografts for Cancer Research

Patient-derived organoids: a promising tool for breast cancer research

The application of patient-derived organoid in the research of lung cancer